Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants.
Saved in:
| Title: | Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants. |
|---|---|
| Authors: | Cui C; Department of Cardiology, Peking University Third Hospital, Beijing, 100191, China.; Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, 100191, China.; Centre of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China., Niu X; Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, 100191, China.; Centre of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China., Li H; Department of Cardiology, Peking University Third Hospital, Beijing, 100191, China.; Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, 100191, China.; Centre of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China., Zhang R; Department of Clinical Pharmacology, Shenzhen Salubris Pharmaceuticals Co. Ltd, Beijing, 100022, China., Geng L; Department of Clinical Pharmacology, Shenzhen Salubris Pharmaceuticals Co. Ltd, Beijing, 100022, China., Lin W; Department of Clinical Operations, Shenzhen Salubris Pharmaceuticals Co. Ltd, Shenzhen, 518000, China., Liu Z; Department of Data Science, Shenzhen Salubris Pharmaceuticals Co. Ltd, Beijing, 100022, China., Wang X; Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, China. sshwang@126.com., Liu D; Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, 100191, China. liudongyang@vip.sina.com.; Centre of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China. liudongyang@vip.sina.com.; Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, 100191, China. liudongyang@vip.sina.com. |
| Source: | Clinical drug investigation [Clin Drug Investig] 2025 Apr; Vol. 45 (4), pp. 179-189. Date of Electronic Publication: 2025 Mar 13. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9504817 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1918 (Electronic) Linking ISSN: 11732563 NLM ISO Abbreviation: Clin Drug Investig Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40074970 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Cui+C%22">Cui C</searchLink>; Department of Cardiology, Peking University Third Hospital, Beijing, 100191, China.; Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, 100191, China.; Centre of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China.<br /><searchLink fieldCode="AU" term="%22Niu+X%22">Niu X</searchLink>; Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, 100191, China.; Centre of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China.<br /><searchLink fieldCode="AU" term="%22Li+H%22">Li H</searchLink>; Department of Cardiology, Peking University Third Hospital, Beijing, 100191, China.; Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, 100191, China.; Centre of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China.<br /><searchLink fieldCode="AU" term="%22Zhang+R%22">Zhang R</searchLink>; Department of Clinical Pharmacology, Shenzhen Salubris Pharmaceuticals Co. Ltd, Beijing, 100022, China.<br /><searchLink fieldCode="AU" term="%22Geng+L%22">Geng L</searchLink>; Department of Clinical Pharmacology, Shenzhen Salubris Pharmaceuticals Co. Ltd, Beijing, 100022, China.<br /><searchLink fieldCode="AU" term="%22Lin+W%22">Lin W</searchLink>; Department of Clinical Operations, Shenzhen Salubris Pharmaceuticals Co. Ltd, Shenzhen, 518000, China.<br /><searchLink fieldCode="AU" term="%22Liu+Z%22">Liu Z</searchLink>; Department of Data Science, Shenzhen Salubris Pharmaceuticals Co. Ltd, Beijing, 100022, China.<br /><searchLink fieldCode="AU" term="%22Wang+X%22">Wang X</searchLink>; Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, China. sshwang@126.com.<br /><searchLink fieldCode="AU" term="%22Liu+D%22">Liu D</searchLink>; Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, 100191, China. liudongyang@vip.sina.com.; Centre of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China. liudongyang@vip.sina.com.; Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, 100191, China. liudongyang@vip.sina.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229504817%22">Clinical drug investigation</searchLink> [Clin Drug Investig] 2025 Apr; Vol. 45 (4), pp. 179-189. <i>Date of Electronic Publication: </i>2025 Mar 13. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase I – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Adis%2C+Springer+International%22">Adis, Springer International </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>9504817 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1179-1918 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211732563%22">11732563 </searchLink><i>NLM ISO Abbreviation: </i>Clin Drug Investig <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40074970 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s40261-025-01428-9 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 179 Titles: – TitleFull: Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Cui C – PersonEntity: Name: NameFull: Niu X – PersonEntity: Name: NameFull: Li H – PersonEntity: Name: NameFull: Zhang R – PersonEntity: Name: NameFull: Geng L – PersonEntity: Name: NameFull: Lin W – PersonEntity: Name: NameFull: Liu Z – PersonEntity: Name: NameFull: Wang X – PersonEntity: Name: NameFull: Liu D IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2025 Apr Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1179-1918 Numbering: – Type: volume Value: 45 – Type: issue Value: 4 Titles: – TitleFull: Clinical drug investigation Type: main |
| ResultId | 1 |
